357 related articles for article (PubMed ID: 23026947)
1. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
2. Histopathology of MPGN and C3 glomerulopathies.
Cook HT; Pickering MC
Nat Rev Nephrol; 2015 Jan; 11(1):14-22. PubMed ID: 25447133
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
4. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
5. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
6. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulopathies. A new perspective on glomerular diseases.
Rabasco-Ruiz C; Huerta-Arroyo A; Caro-Espada J; Gutiérrez-Martínez E; Praga-Terente M
Nefrologia; 2013; 33(2):164-70. PubMed ID: 23511752
[TBL] [Abstract][Full Text] [Related]
8. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
9. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
10. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
[TBL] [Abstract][Full Text] [Related]
11. Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.
Lionaki S; Gakiopoulou H; Boletis JN
APMIS; 2016 Sep; 124(9):725-35. PubMed ID: 27356907
[TBL] [Abstract][Full Text] [Related]
12. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification.
Sethi S; Fervenza FC
Semin Nephrol; 2011 Jul; 31(4):341-8. PubMed ID: 21839367
[TBL] [Abstract][Full Text] [Related]
13. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
14. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
15. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
16. Membranoprolferative glomerulonephritis - mechanisms and treatment.
Appel GB
Contrib Nephrol; 2013; 181():163-74. PubMed ID: 23689578
[TBL] [Abstract][Full Text] [Related]
17. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
19. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III.
Varade WS; Forristal J; West CD
Am J Kidney Dis; 1990 Sep; 16(3):196-206. PubMed ID: 2205097
[TBL] [Abstract][Full Text] [Related]
20. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]